Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome
Open accessThe DOI matches its Crossref record; 18 of the 19 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The cryopyrin-associated periodic syndrome (CAPS) is a rare inherited inflammatory disease associated with overproduction of interleukin-1. Canakinumab is a human anti-interleukin-1beta monoclonal antibody. METHODS: We performed a three-part, 48-week, double-blind, placebo-controlled, randomized withdrawal study of canakinumab in patients with CAPS. In part 1, 35 patients received 150 mg of canakinumab subcutaneously. Those with a complete response to treatment entered part 2 and were randomly assigned to receive either 150 mg of canakinumab or placebo every 8 weeks for up to 24 weeks. After the completion of part 2 or at the time of relapse, whichever occurred first, patients proceeded to part 3 and received at least two more doses of canakinumab. We evaluated therapeutic responses using disease-activity scores and analysis of levels of C-reactive protein (CRP) and serum amyloid A protein (SAA). RESULTS: In part 1 of the study, 34 of the 35 patients (97%) had a complete response to canakinumab. Of these patients, 31 entered part 2, and all 15 patients receiving canakinumab remained in remission. Disease flares occurred in 13 of the 16 patients (81%) receiving placebo (P<0.001). At the end of part 2, median CRP and SAA values were normal (<10 mg per liter for both measures) in patients receiving canakinumab but were elevated in those receiving placebo (P<0.001 and P=0.002, respectively). Of the 31 patients, 28 (90%) completed part 3 in remission. In part 2, the incidence of suspected infections was greater in the canakinumab group than in the placebo group (P=0.03). Two serious adverse events occurred during treatment with canakinumab: one case of urosepsis and an episode of vertigo. CONCLUSIONS: Treatment with subcutaneous canakinumab once every 8 weeks was associated with a rapid remission of symptoms in most patients with CAPS. (ClinicalTrials.gov number, NCT00465985.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Interestingly, IL-1RA-blocking Ab (anakinra) and IL-1β-blocking Ab (canakinumab) are already FDA approved as anti-inflammatory biologics for the treatment of rheumatoid arthritis (130) and NLRP3-inflammasome-mediated cryopyrin-associated periodic syndrome (CAPS) (131), respectively.”
From Pathophysiology of Sickle Cell Disease (2019) · cites this paper as [131]
Citations
Cites
Natural History and Outcome in Systemic AA Amyloidosis
Lachmann, H. J., Goodman, H. J. B., Gilbertson, J. A., Gallimore, J. R., Sabin, C. A., Gillmore, J. D., & Hawkins, P. N. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070265 · Cited by 1,032
Self-citationSpectrum of clinical features in Muckle‐Wells syndrome and response to anakinra
Hawkins, P. N., Lachmann, H. J., Aganna, E., & McDermott, M. F. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20033 · Cited by 744
Self-citationHoffman, H. M., Throne, M. L., Amar, N. J., Sebai, M., Kivitz, A. J., Kavanaugh, A., Weinstein, S. P., Belomestnov, P., Yancopoulos, G. D., Stahl, N., et al. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23687 · Cited by 577 · cited 2×
“Viral infection 0 2 (13) 0 0 Headache 0 2 (13) 0 3 ( 10 )”
URTICARIA, DEAFNESS, AND AMYLOIDOSIS: A NEW HEREDO-FAMILIAL SYNDROME
(1962) · QJM: An International Journal of Medicine · doi:10.1093/oxfordjournals.qjmed.a066967 · Cited by 372
In vivo regulation of interleukin 1β in patients with cryopyrin-associated periodic syndromes
Lachmann, H. J., Lowe, P., Felix, S. D., Rordorf, C., Leslie, K., Madhoo, S., Wittkowski, H., Bek, S., Hartmann, N., Bosset, S., et al. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20082481 · Cited by 312
Self-citationPrimer: inflammasomes and interleukin 1β in inflammatory disorders
Church, L. D., Cook, G. P., & McDermott, M. F. (2008) · Nature Clinical Practice Rheumatology · doi:10.1038/ncprheum0681 · Cited by 309
Furst, D. E., Breedveld, F. C., Kalden, J. R., Smolen, J. S., Burmester, G. R., Bijlsma, J. W. J., Dougados, M., Emery, P., Keystone, E. C., Klareskog, L., et al. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2005.044941 · Cited by 225
Leslie, K. S., Lachmann, H. J., Bruning, E., McGrath, J. A., Bybee, A., Gallimore, J. R., Roberts, P. F., Woo, P., Grattan, C. E., & Hawkins, P. N. (2006) · Archives of Dermatology · doi:10.1001/archderm.142.12.1591 · Cited by 186 · cited 13×
“Rhinitis 4 (11) 1 (7) 2 (12) 0 Bronchitis 3 (9) 1 ( 7 ) 1 (6) 0”
InfluentialSelf-citationAlten, R., Gram, H., Joosten, L. A., Berg, W. B. V. D., Sieper, J., Wassenberg, S., Burmester, G., van Riel, P., Diaz-Lorente, M., Bruin, G. J., et al. (2008) · Arthritis Research & Therapy · doi:10.1186/ar2438 · Cited by 170
The many worlds of reducing interleukin‐1
Dinarello, C. A. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21107 · Cited by 104
Research works printed but not linked: 5
- Muckle TJ, 1962, Q J Med, 31, 235
- Lachmann HJ, 2008, Clin Exp Rheumatol, 26, 181
- Kuemmerle-Deschner JB, 2008, Clin Exp Rheumatol, 26, 180
- Kummerle-Deschner J, 2008, Ann Rheum Dis, 67, 104
- Maier J, 2008, J Rheumatol, 35, 939
Cited by
Items 801–869 of 869
Autoinflammatorische Erkrankungen
Feist, E., & Henes, J. C. (2019) · Springer Reference Medizin · doi:10.1007/978-3-642-54676-1_92-1
New drugs: Sapropterin dihydrochloride
(2011) · Australian Prescriber · doi:10.18773/austprescr.2011.034
(2011) · Australian Prescriber · doi:10.18773/austprescr.2011.032
Lehmann, H., & Huppertz, H.-I. (2014) · Springer eBooks · doi:10.1007/978-3-642-41814-3_176
Industry Update: the Latest Developments in Therapeutic Delivery
Rees, G. D. (2011) · Therapeutic Delivery · doi:10.4155/tde.11.136
Hausmann, J. S., & Dedeoğlu, F. (2019) · Springer eBooks · doi:10.1007/978-3-030-16928-2_13
Ward, B. R. (2016) · Compendium of Inflammatory Diseases · doi:10.1007/978-3-7643-8550-7_188
Faculty Opinions recommendation of IL-1 blockade in autoinflammatory syndromes.
Lopez-Escamez, J. A. (2018) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.718239727.793549284
(2011) · Australian Prescriber · doi:10.18773/austprescr.2011.035
Gattorno, M. (2012) · Springer eBooks · doi:10.1007/978-3-642-02202-9_170
Periodic fever syndromes and autoinflammatory diseases
Guerra, A. A. H., & Dimitriades, V. R. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-95061-9.00029-1
Alam, M., Mah, A., & Belga, S. (2022) · Springer eBooks · doi:10.1007/978-3-031-11363-5_9
Insights in Pediatric Rheumatology: 2021
Cattalini, M., Levy, D., & Cimaz, R. (2023) · Frontiers research topics · doi:10.3389/978-2-8325-1205-0
Chen, S., Fu, Z., Yu, C., Liu, C., Li, M., Wu, G., Guo, X. H., Liu, X., Wang, L., & Wang, J. (2023) · Analytical Science Advances · doi:10.1002/ansa.202200019
“20 In addition, canakinumab has a long half-life, so it can be injected infrequently or in small doses to block IL-1 β for a long time.”
BackgroundThe Role of Inflammasome in Cancers and Potential Therapeutic Targets
Farhangnia, P., Safdarian, A. R., & Akbarpour, M. (2023) · Springer eBooks · doi:10.1007/978-3-030-80962-1_70-1 · Cited by 1
From Bench to Bedside: Targeting the IL-1β Pathway in Autoinflammatory Diseases
McEvoy, L. (2016) · EMJ Rheumatology · doi:10.33590/emjrheumatol/10312871
Wenn Kälte Ausschlag und viele Beschwerden macht
Holl‐Wieden, A. (2023) · Springer eBooks · doi:10.1007/978-3-662-66617-3_25
Kimura, Y., Aiba, S., Ashikaga, T., Ohishi, T., & Kushima, K. (2023) · OECD series on adverse outcome pathways · doi:10.1787/74834ad1-en
Principles of Systemic Therapy
Pink, A., Woolf, R., & Smith, C. H. (2024) · Wiley eBooks · doi:10.1002/9781119709268.rook019
Schreml, S. (2024) · Wiley eBooks · doi:10.1002/9781119709268.rook056
When Cold Causes Rash and Many Complaints
Holl‐Wieden, A. (2024) · Springer eBooks · doi:10.1007/978-3-662-68732-1_25
Enfermedades autoinflamatorias monogénicas
Koné‐Paut, I., & Dusser, P. (2024) · EMC - Aparato Locomotor · doi:10.1016/s1286-935x(24)49134-x
Yamamoto, T. (2024) · Nihon Shoni Arerugi Gakkaishi The Japanese Journal of Pediatric Allergy and Clinical Immunology · doi:10.3388/jspaci.38.218
Therapeutic Approaches for Periodic Fever Syndromes and Autoinflammatory Disorders
Guerra, A. A. H., & Dimitriades, V. R. (2025) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2025.01.006 · Cited by 1
Understanding the role of the inflammasomes in human keratinocytes
Rozario, P. (2024) · DR-NTU (Nanyang Technological University) · doi:10.32657/10356/183603
Rare autoinflammatory and miscellaneous diseases
(2025) · Oxford University Press eBooks · doi:10.1093/med/9780198885153.003.0018
Bioterapias en dermatología (cáncer no incluido)
Villani, A. P., & Jullien, D. (2025) · EMC - Dermatología · doi:10.1016/s1761-2896(25)50750-1
Abudayeh, A. H., & Fishchenko, I. V. (2025) · Clinical Rheumatology · doi:10.1007/s10067-025-07777-2
“Neutralization of IL-1β is the mechanism of action of canakinumab, a distinct monoclonal antibody approved for autoinflammatory syndromes and systemic juvenile idiopathic arthritis [4].”
Satirer, Y., Şatırer, Ö., Benseler, S. M., & Kuemmerle-Deschner, J. B. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14238268
“The inclusion criteria were as follows: (1) an established diagnosis of CAPS or FMF according to published criteria [1,4,12]; (2) age ≥ 8 years at the last visit [13], and (3) evidence of inactive disease either on or off treatment at the last follow-up visit [14].”
InfluentialSelf-citationDas Immunsystem – Regelgröße zur Beeinflussung der Zusammensetzung des Mikrobioms?
Bechberger, M. (2024) · heiDOK (Heidelberg University) · doi:10.11588/heidok.00035389
Kuemmerle-Deschner, J. B., Ramos, E., Blank, N., Roesler, J., Felix, S. D., Jung, T., Stricker, K., Chakraborty, A., Tannenbaum, S., Wright, A. M., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12877390
Self-citationHur, P., Lomax, K. G., Ionescu‐Ittu, R., Manceur, A. M., Xie, J., Cammarota, J., Gautam, R., Sanghera, N., Kim, N., & Grom, A. A. (2021) · Figshare · doi:10.6084/m9.figshare.16620931
Additional file 1 of Tapering of biological treatment in autoinflammatory diseases: a scoping review
Welzel, T., Oefelein, L., Twilt, M., Pfister, M., Kuemmerle-Deschner, J. B., & Benseler, S. M. (2022) · Figshare · doi:10.6084/m9.figshare.20486626
Self-citationKuemmerle-Deschner, J. B., Ramos, E., Blank, N., Roesler, J., Felix, S. D., Jung, T., Stricker, K., Chakraborty, A., Tannenbaum, S., Wright, A. M., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12877387
Self-citationKuemmerle-Deschner, J. B., Ramos, E., Blank, N., Roesler, J., Felix, S. D., Jung, T., Stricker, K., Chakraborty, A., Tannenbaum, S., Wright, A. M., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12877396
Self-citationKuemmerle-Deschner, J. B., Ramos, E., Blank, N., Roesler, J., Felix, S. D., Jung, T., Stricker, K., Chakraborty, A., Tannenbaum, S., Wright, A. M., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12877393
Self-citationBender, T. T. A., Leyens, J., Sellin, J., Kravchenko, D., Conrad, R., Mücke, M., & Seidel, M. F. (2020) · Figshare · doi:10.6084/m9.figshare.13174015
Solís-Moruno, M. (2021) · Repositori digital de la UPF (Universitat Pompeu Fabra)
The Role of Inflammasome in Cancers and Potential Therapeutic Targets
Farhangnia, P., Safdarian, A. R., & Akbarpour, M. (2025) · Springer eBooks · doi:10.1007/978-3-032-00771-1_70
Développement de nouveaux inhibiteurs du TNFα identifiés par Drug Design
Mouhsine, H. (2012) · theses.fr (ABES) · doi:10.70675/2398d5cfz5c4cz40b1z8207zac2e91a015ea
Segueni, N. (2015) · theses.fr (ABES) · doi:10.70675/534760f2zfac7z4304z979azd00b2fb6136c · Cited by 1
Hassane, M. (2016) · theses.fr (ABES) · doi:10.70675/6473619bz70baz4059zb574z0366a9fcdaf4
Assrawi, E. (2019) · theses.fr (ABES) · doi:10.70675/82f530d5z0154z474cz9746z470b6a42c9e0
Étude de l’influence de la glutaminolyse des macrophages dans les maladies cardio-métaboliques
Merlin, J. (2020) · theses.fr (ABES) · doi:10.70675/68e10f28zf840z48bfz9bacz5511a3a2b208
Louvrier, C. (2019) · theses.fr (ABES) · doi:10.70675/ee57af23z15cdz4ec8zafebz9f9ac9f08220
Bayındır, Y., Şatırer, Ö., Çam, V., Türkmen, Ş., Sozeri, B., Kuemmerle-Deschner, J. B., & Özen, S. (2026) · Pediatric Rheumatology · doi:10.1186/s12969-026-01214-7
“…remission was defined as PGA ≤ 2, with CRP ≤ 0.5 mg/dl and/or SAA ≤ 10 mg/L. • Partial remission was defined as PGA > 2 and ≤ 5, with CRP > 0.5 mg/dl but ≤ 3 mg/dl and/or SAA > 10 mg/L but ≤ 30 mg/dl. • Non-remission was defined as PGA > 5, with CRP > 3 mg/dl and/or SAA > 30 mg/dl [13, 14].”
InfluentialSelf-citationPérez, M. I. L., Conde, J. C. Q., Carbajo, D. L., González, L. J., & Barandica, G. B. (2026) · The European Journal of Contraception & Reproductive Health Care · doi:10.1080/13625187.2026.2666796
The Liver in Pediatric Rheumatology: A Comprehensive Review
Jariwala, M. P., Kerr, T., & Kehar, M. (2026) · Livers · doi:10.3390/livers6030037
Synthetic Biology for Drug Repurposing
Haq, E. U., Khan, M. A., Mujahid, K., & Babar, M. M. (2026) · Springer eBooks · doi:10.1007/978-981-95-3957-4_29
Therapeutics: Biologics and Targeted Small Molecules
Verstegen, R. H. J., Ruperto, N., & Brunner, H. I. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-11980-4.00013-1
IL-1–targeted therapy in dermatologic conditions
Balan, K., & Elston, D. M. (2026) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2026.06.021
Mitrovic, S., Hentgen, V., Delplanque, M., Ea, H., Frémond, M., Georgin‐Lavialle, S., Jamilloux, Y., Koné‐Paut, I., Pascart, T., Quartier, P., et al. (2026) · Revue du Rhumatisme · doi:10.1016/j.rhum.2026.05.010
Self-citationMitrovic, S., Delplanque, M., Ea, H., Frémond, M., Georgin‐Lavialle, S., Hentgen, V., Jamilloux, Y., Koné‐Paut, I., Pascart, T., Quartier, P., et al. (2026) · Revue du Rhumatisme · doi:10.1016/j.rhum.2026.05.009
Self-citationJamilloux, Y., Delplanque, M., Ea, H., Frémond, M., Georgin‐Lavialle, S., Hentgen, V., Koné‐Paut, I., Pascart, T., Quartier, P., Richette, P., et al. (2026) · Revue du Rhumatisme · doi:10.1016/j.rhum.2026.06.007
Self-citationFrémond, M., Quartier, P., Delplanque, M., Ea, H., Georgin‐Lavialle, S., Hentgen, V., Jamilloux, Y., Koné‐Paut, I., Pascart, T., Richette, P., et al. (2026) · Revue du Rhumatisme · doi:10.1016/j.rhum.2026.06.011
Self-citationErasani, G., Choma, N., & Ifteqar, S. (2026) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.70667
“It has demonstrated efficacy in diseases mediated by IL-1β, such as cryopyrin-associated periodic syndromes and systemic juvenile idiopathic arthritis [9].”
Christiaenssen, B., Mortelmans, S., Baghli, S., Boone, F., Xie, W., Bertoni, A., Ha, M., Ogunjimi, B., Sabato, V., Gattorno, M., et al. (2026) · Cell Death and Differentiation · doi:10.1038/s41418-026-01821-7
Arsiwala, N., & Rigante, D. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15176795
“Equally important, colchicine is not effective for TRAPS, CAPS and sJIA, in which the risk must be managed through different pharmacological pathways [14,20,21].”
InfluentialŞatırer, Ö., Hospach, A., Parczyk, N., Benseler, S. M., & Kuemmerle-Deschner, J. B. (2026) · EULAR Rheumatology Open · doi:10.1016/j.ero.2026.100245
“Although both anakinra and canakinumab inhibit IL-1, anakinra is often preferred for CNS disease because of superior blood-brain barrier penetration; cerebrospinal fl uid (CSF) in fl ammation may persist under cana-kinumab [3,4].”
Self-citationYang, Y.-S., Gross, K. Y., Cooper, D., Chaugule, S. R., Kim, M., Dahlke, C. D., Mayer, E., Kercher, E. M., Kim, J. W., Ormsby, T. J. R., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-78738-9
Kurata, M., Takahashi, K., Kaneko, N., Kameda, K., Nakamura, T., Hosokawa, S., Murakami, K., Ogura, H., Ishido, S., Yamaguchi, O., et al. (2026) · The Journal of Immunology · doi:10.1093/jimmun/vkag257
Şatırer, Ö., Bogenschütz, M., Benseler, S. M., & Kuemmerle-Deschner, J. B. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15218232
Self-citationBindingDB (2025) · UC San Diego · doi:10.7270/q21j9gck
Molecular underpinnings of rheumatic diseases and emerging therapeutic concepts
Krönke, G., Schett, G. A., & Latz, E. (2026) · Nature · doi:10.1038/s41586-026-10966-x
“…recombinant proteins are already successfully used to cope with the full spectrum of IL-1-driven autoinflammatory IRDs including gout, Still’s disease and cryopyrin-associated periodic syndromes 127–129 , and new small-molecule inhibitors for NLRP3 are currently in clinical development 130,131 .”
How to Diagnose and Manage Systemic Autoinflammatory Diseases in Childhood
Bonnekoh, H., & Krause, K. (2015) · Current Treatment Options in Allergy · doi:10.1007/s40521-015-0061-1 · Cited by 1
Metadata
- Authors
- Lachmann, H. J., Kone-Paut, I., Kuemmerle-Deschner, J. B., Leslie, K. S., Hachulla, E., Quartier, P., Gitton, X., Widmer, A., Patel, N., & Hawkins, P. N.
- Affiliations
- University College London (GB)
- Universitätsklinikum Tübingen (DE)
- University of California, San Francisco (US)
- Université de Lille (FR)
- Hôpital Necker-Enfants Malades (FR)
- Novartis (Switzerland) (CH)
- Novartis (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-06-04
- Volume
- 360
- Issue
- 23
- Pages
- 2416-2425
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2149374693
- Cited by
- 869
- References
- 19
- Citations by year
- 2026: 23 · 2025: 30 · 2024: 31 · 2023: 23 · 2022: 37 · 2021: 40 · 2020: 53 · 2019: 56 · 2018: 34 · 2017: 38 · 2016: 55 · 2015: 67 · 2014: 50 · 2013: 66 · 2012: 73
- FWCI
- 35.40
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Novartis Pharma
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
- Health Sciences › Medicine › Hematology › Autoimmune and Inflammatory Disorders Research
- Life Sciences › Immunology and Microbiology › Immunology › Immunodeficiency and Autoimmune Disorders
- Keywords
- canakinumab, cryopyrin-associated periodic syndromes, IL-1β, interleukin-1 receptor antagonist, familial cold autoinflammatory syndrome, Muckle-Wells syndrome, disease flares, C-reactive protein, serum amyloid A, infection risk, urosepsis, vertigo, treatment withdrawal
- MeSH terms
- NLR Family, Pyrin Domain-Containing 3 Protein, Adolescent, Adult, Aged, Antibodies, Monoclonal, Carrier Proteins, Child, Double-Blind Method, Female, Humans, Male, Middle Aged, Mutation, Familial Mediterranean Fever, Interleukin-1beta, Young Adult, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.